Trial Profile
A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Andexanet alfa (Primary)
- Indications Intracranial haemorrhages
- Focus Registrational; Therapeutic Use
- Acronyms ANNEXa-I
- Sponsors Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals
- 08 Jan 2024 This trial has been Discontinued in Finland, according to European Clinical Trials Database record.
- 05 Nov 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 11 Sep 2023 Status changed from active, no longer recruiting to completed.